Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL1022490 | 0.92 | HRH4 (0.33) | — | |
| Benzene SCHEMBL1449616 | 0.88 | — | — | |
| Benzene SCHEMBL3243648 | 0.72 | CHRNA7 (0.40) | — | |
| Benzene SCHEMBL2929682 | 0.70 | CHRNA7 (0.44) | — | |
| SCHEMBL3055453 | 0.68 | MBTD1 (0.51) | KMT2A | |
| Benzene SCHEMBL3552917 | 0.68 | CHRNA3 (0.33) | — | |
| Benzene SCHEMBL2930414 | 0.66 | CHRNB2 (0.46) | — | |
| SCHEMBL5375837 | 0.65 | CHRNB2 (0.52) | — | |
| SCHEMBL5832829 | 0.64 | HRH3 (0.44) | — | |
| SCHEMBL5832685 | 0.63 | CHRNA7 (0.58) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662812-B2 | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | claimed |
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | NEUROSEARCH A/S (DK) | 2008-06-19 | — | — | US | claimed |
| EP-1863819-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHINOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2007-12-12 | — | — | EP | claimed |
| WO-2006087306-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2006-08-24 | — | — | WO | claimed |
| US-7662812-B2 | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | NEUROSEARCH A/S (DK) | 2008-06-19 | — | — | US | disclosed |
| EP-1863819-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHINOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006087306-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | CHRNA6, CHRNA10, CHRNA2 | LMNA 1795/4885KMT2A 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.